NCT02364453View on ClinicalTrials.gov

The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Migraine Without Aura
Interventions
DRUG

PACAP38

Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.

Trial Locations (1)

2600

Danish Headache Center & Department of Neurology, Copenhagen

All Listed Sponsors
lead

Song Guo

OTHER

NCT02364453 - The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients | Biotech Hunter | Biotech Hunter